FDA placed a clinical hold on a gene therapy involving Hunter.
1 report, 1 independent
Updated Aug 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA placed a clinical hold on a gene therapy involving Hunter.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- Research advances have led to the approval of new therapies by the FDA.
- FDA approval expands patient access to therapies for ACCORD.
- Arise is seeking FDA approval for a drug as of October 7, 2026.